255 related articles for article (PubMed ID: 27913620)
21. Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain.
Chen SP; Zhou YQ; Wang XM; Sun J; Cao F; HaiSam S; Ye DW; Tian YK
Pharmacol Res; 2019 Sep; 147():104339. PubMed ID: 31276771
[TBL] [Abstract][Full Text] [Related]
22. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
[TBL] [Abstract][Full Text] [Related]
23. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
[No Abstract] [Full Text] [Related]
24. α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β
Ebrahimi T; Rust M; Kaiser SN; Slowik A; Beyer C; Koczulla AR; Schulz JB; Habib P; Bach JP
J Neuroinflammation; 2018 Sep; 15(1):282. PubMed ID: 30261895
[TBL] [Abstract][Full Text] [Related]
25. NLRP3 inflammasome inhibition attenuates subacute neurotoxicity induced by acrylamide in vitro and in vivo.
Sui X; Yang J; Zhang G; Yuan X; Li W; Long J; Luo Y; Li Y; Wang Y
Toxicology; 2020 Feb; 432():152392. PubMed ID: 32014472
[TBL] [Abstract][Full Text] [Related]
26. MCC950 closes the active conformation of NLRP3 to an inactive state.
Tapia-Abellán A; Angosto-Bazarra D; Martínez-Banaclocha H; de Torre-Minguela C; Cerón-Carrasco JP; Pérez-Sánchez H; Arostegui JI; Pelegrin P
Nat Chem Biol; 2019 Jun; 15(6):560-564. PubMed ID: 31086329
[TBL] [Abstract][Full Text] [Related]
27. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
28. Inflammation: Targeting the NLRP3 inflammasome after MI.
Lim GB
Nat Rev Cardiol; 2016 Sep; 13(9):506. PubMed ID: 27489192
[No Abstract] [Full Text] [Related]
29. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
Kammoun HL; Allen TL; Henstridge DC; Barre S; Coll RC; Lancaster GI; Cron L; Reibe S; Chan JY; Bensellam M; Laybutt DR; Butler MS; Robertson AAB; O'Neill LA; Cooper MA; Febbraio MA
Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
[TBL] [Abstract][Full Text] [Related]
30. Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis.
Fu R; Guo C; Wang S; Huang Y; Jin O; Hu H; Chen J; Xu B; Zhou M; Zhao J; Sung SJ; Wang H; Gaskin F; Yang N; Fu SM
Arthritis Rheumatol; 2017 Aug; 69(8):1636-1646. PubMed ID: 28544564
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
33. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
van Hout GP; Bosch L; Ellenbroek GH; de Haan JJ; van Solinge WW; Cooper MA; Arslan F; de Jager SC; Robertson AA; Pasterkamp G; Hoefer IE
Eur Heart J; 2017 Mar; 38(11):828-836. PubMed ID: 27432019
[TBL] [Abstract][Full Text] [Related]
34. H5N1 Influenza A Virus PB1-F2 Relieves HAX-1-Mediated Restriction of Avian Virus Polymerase PA in Human Lung Cells.
Mazel-Sanchez B; Boal-Carvalho I; Silva F; Dijkman R; Schmolke M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563290
[TBL] [Abstract][Full Text] [Related]
35. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
36. Adiponectin reduces brain injury after intracerebral hemorrhage by reducing NLRP3 inflammasome expression.
Wang S; Yao Q; Wan Y; Wang J; Huang C; Li D; Yang B
Int J Neurosci; 2020 Mar; 130(3):301-308. PubMed ID: 31607194
[No Abstract] [Full Text] [Related]
37. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
38. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
39. Activation of NLRP3 inflammasome up-regulates TREM-1 expression in murine macrophages via HMGB1 and IL-18.
Zhong WJ; Duan JX; Liu T; Yang HH; Guan XX; Zhang CY; Yang JT; Xiong JB; Zhou Y; Guan CX; Li Q
Int Immunopharmacol; 2020 Dec; 89(Pt A):107045. PubMed ID: 33045564
[TBL] [Abstract][Full Text] [Related]
40. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
